StockData

BGM vs BioHarvest Sciences

BGM and BHST side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BGM and BHST compare

BGM grew revenue faster over the last twelve months (51.1% versus 37.0% for BioHarvest Sciences).

BioHarvest Sciences keeps more of each dollar of sales as profit, with a net margin of −32.3% compared with −52.6% at BGM.

BGM scores higher on the StockData Score (9 against 5 for BioHarvest Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBGMBHST
Size and price
Share price$7.88$1.50
Change, 1 year−97.2%−80.9%
Change, 5 years−98.4%−86.1%
Beta (5Y)0.270.87
Employees206–
StockData Score
Total score9 (better)5
Valuation score00
Growth score22
Performance score2 (better)1
Health score5 (better)2
Dividend score00
Growth
Revenue growth (TTM)51.1% (better)37.0%
Revenue growth, 5Y average−5.4%–
Profitability
Gross margin16.6%59.3% (better)
Operating margin−33.2%−16.2% (better)
Net margin−52.6%−32.3% (better)
FCF margin−10.4% (better)−27.8%
Return on equity−9.2% (better)−83.2%
Return on invested capital−4.8% (better)−163%
Financial health
Debt / equity0.000.01 (better)
Current ratio1.243.97 (better)
Piotroski F-score45 (better)
Ownership
Held by institutions0.00%7.4%
Held by insiders52.5%0.00%
Short interest, % of float0.00%0.33%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.